iObserver Version 1.9 Is Released by Caregility: A Continous Virtual Observation & Communications Systems for Monitoring Patients Remotely

November 19, 2020

Caregility, a clinical collaboration and communications company moving the access point of care closer to the patient, announces the release of version 1.9 of its iObserver application, a continuous virtual observation and communications system for remotely monitoring at-risk patients.

iObserver allows clinical teams to remotely observe up to 12 patient rooms on a single screen with two-way audio and video support through the Caregility Platform, a purpose-built, HIPAA-compliant telehealth ecosystem for the entire healthcare continuum.

Caregility leveraged thousands of hours of customer input to build new features and capability into the iObserver v1.9 release. The new version will enhance patient and provider experience and application flexibility with the goals of minimizing adverse events, easing provider burden, and reducing healthcare costs by enabling care teams to do more with less.

Costs associated with the patient sitting are rarely reimbursed and often unbudgeted. With expenses for in-room patient sitters running into the millions, this can have a significant impact on a hospital’s bottom-line and direct care resources.  One Caregility healthcare customer, after deploying iObserver, reported that in eight months of use their unbudgeted sitter hours dropped by 75% with no falls or adverse events.

iObserver enables cost-effective virtual observation across a broad spectrum of use cases, including but not limited to:

  • Clinical deterioration/rapid response events
  • Fall prevention/elopement
  • COVID isolation room – bedside support and room visualization
  • Overflow capacity management
  • Risk to self, from others, or to others

“Caregility is committed to investing in accelerated development that takes into account the experience from both the clinical perspective and the patient perspective,” said Sudhir Ahuja, SVP of Product Development at Caregility. “The iObserver v1.9 release is a great example of taking that input and turning it into a reality for our customers.”

To see a demonstration of how iObserver can help your health system protect patients and drive down costs, as well as unique options we have to help you deal with rising COVID cases with our bedside application that turns any iPad in to a secure communications device in patient rooms, contact Caregility at (732) 440-8040.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version